NEUROPATHIC OCULAR PAIN MARKET ANALYSIS
Global Neuropathic Ocular Pain Market: Key Developments
In May 2022, AERIE PHARMACEUTICALS, INC., an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma, retinal diseases, and other diseases of the eye, announced that it had begun phase –III clinical trials of drug candidate AR-15512, to treat dry eye disease and eye inflammation.
In May 2020, BRIM Biotechnology, Inc., a clinical-stage pharmaceutical company involved in drug discovery and development of chronic diseases, announced that it is developing BRM421, a synthetic peptide comprising 29 amino acids, for the treatment of dry eye syndrome.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :